Member Info for Porter_

Genflow are currently working in collaboration with industry experts as follows:

Two major animal health companies:

Genflow is in discussions with these firms to explore licensing its SIRT6-based gene therapy platform for use in companion animals. These collaborations are expected to accelerate market entry by leveraging the expertise and commercial infrastructure of the larger companies.

Syngene:

An independent contract research organization (CRO) managing Genflow's GF-1004 dog aging study. This study involves beagles aged 10+ years and aims to provide preclinical data to support future licensing deals.

Revatis SA:

Partnering on a sarcopenia (age-related muscle loss) research program.

EXO Biologics:

Collaborating on an exosome-mRNA project.

Heureka Labs, Inc.:

Partnering to use AI technology for genomic data analysis.

CER Groupe:

A long-standing R&D collaborator with whom Genflow signed a master service agreement in May 2025.

University of Rochester, Columbia University, and Albert Einstein College of Medicine:

Collaborative partners who exclusively license their patent EP4338267 to Genflow Biosciences.

The timing of the announcement has peaked my interest money.

Trials haven’t even concluded and yet pharma are trying to line up agreements.

I know Genflow have the 4m grant money and 2 patents which could land any day, but I feel like there is more we’re not being told. All good!

With 5 programmes, + compound variants and different patient groups the science could relate to, there is a lot to gain should big pharma take it all.

Sounds good Money. Revenue generating with no need to draw upon diluting funding. Seems like the roadmap is being delivered exactly as the team promised!

I’d hope Eric is smart enough that if he has 2 separate companies interested, their access to IP won’t infringe on the other and he can do a deal with both. Such as one that specialises in vaccinations, and the other than specialises in food distribution, with no conflict of interest either side. We could see 2 big deals inked, as opposed to 1 🙏🏻

Don’t companies usually sign CDA’s as a first step to acquisition or commercial licensing?

Would be amazing if Genflow are in negotiations with 2 pet pharma / food retail giants 👀

In June 2025, JB Pharma acquired Torrent Pharma, in a deal worth $3bn, to access the companies ophthalmology programmes:

https://www.pharmaceutical-technology.com/news/torrent-pharmaceuticals-stake-jb-pharma/

In July 2025, Harrow, Inc. announced an agreement with Samsung Bioepis to acquire the U.S. commercial rights for two ophthalmology biosimilars. These treatments are for retinal diseases.

Then there is Genflow Biosciences, with a total MCAP of £4m. Could their eye programme be one to watch?:

GF-1006 (Ophthalmology): A gene therapy for eye diseases like corneal pathologies and glaucoma.

Summary of funding:

- 26th March 2025 - £484,000 investment towards new dog trial programme

- 22nd October 2024 - 4m Euro's non dilutive grant / loan (Wallonia Region)

- 30th May 2024 - 800,000 Euro's non dilutive grant (Government of Wallonia in Belgium's Advanced Therapy Medicinal Products)

- 4th April 2024 - £715,000 Capital Plus Partners placing, new TR1 private investor and new institutional investors

- 18th January 2024 - 1.34m Euro's non dilutive grant

- 18th January 2024 - 1.55m Euro's non dilutive grant

- 11th October 2022 - 250,000 Euro's non dilutive grant (Applied Research Programme of Enterprise Estonia)

- 16th March 2022 - 3.375m Euro's non dilutive grant (Regional Government of Wallonia

Agree Jamtart. This is the life’s work of the team, and no point handing it over too early for others to take the recognition. The team are all very established with-in the industry and not desperate to be picked off for pennies.

Genflow Biosciences' pipeline includes several programs targeting age-related conditions in both humans and animals:

GF-1002 (Human): The lead intravenous gene therapy candidate for use in humans. It is being advanced for conditions like Metabolic Dysfunction-Associated Steatohepatitis (MASH), a liver disease.

GF-1004 (Veterinary): A non-human version of GF-1002, this gene therapy is being developed for dogs to address age-related decline.

GF-1003 (Topical): A gene therapy designed for topical delivery to the skin.

GF-1005 (Sarcopenia): A program addressing mitochondrial dysfunction related to muscle decline.

GF-1006 (Ophthalmology): A gene therapy for eye diseases like corneal pathologies and glaucoma.

Clinical trials and development:

Canine trial: In 2025, Genflow initiated a proof-of-concept trial for GF-1004 in older dogs to study its effects on age-related issues.

MASH trial: The company plans to commence a human clinical trial for GF-1002 to investigate its potential in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Regulatory focus:

The company is prioritizing its application for clinical trial authorization with the European Medicines Agency (EMA).

Might not even get to human trails if the patent is awarded and initial proof of concept is enough to snag a takeover bid.

Equivalent of 1.7p printed in the US. Up 34%. Hopefully good news tomorrow!

I’m sitting around 0.8%, but collectively the float looks tight! The dog trial and eye programme, plus Rochester officially bagging that year 4 patent approval ahead of B1 show this unicorn could take flight any day!

If that was you, you must have some holding now! Will be giving me a run for my money 😆

£10k logged unknown today, same yesterday. Both look like buys and someone passively loading what they can get of the freefloat, ahead of official grant news!

Not seeing the £10k print yet… late trade maybe? Buyers hoovering up meeting sellers on the way back up now!

Pharma took over the LSE top risers board yesterday.

Eyes on Genflow, with billion dollar deals per programme being fetched in the industry.

Genflow have 5 innovative programmes that big pharma would love to get their hands on once IP protected. Institutions are already out there testing Genflow’s IP and saying it works, even if the team are guarding their research tightly until full medical board approval!

It feels like we’re very close to patent sign off, dog trial licensing and further deals.

I can see why the lights are going on and positions are being built!

If Swann increasing his holding isn’t a sign of confidence, then I don’t know what is!

The Directors still have authorisation to buy shares on the open market, will they seize the opportunity before the prospect of major news?

All that loading, with another 2m buys printed as unknown, and still showing down. Big news seems imminent based on this share grab 👏🏻

Acker, you must have been invested since 2020 then, as that’s the last time anyone truly believed the plant was going to work tomorrow

Acker, does that mean the flotation plant still isn’t operational? Sounds like this RNS is the biggest pump and dump of August 2025